Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 14/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224216 | 1.00 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| SCHEMBL1952544 | 1.00 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| SCHEMBL4425446 | 1.00 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| SCHEMBL1952051 | 1.00 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| SCHEMBL1841059 | 1.00 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL954680 | 0.98 | NOS1 (0.51) | NOS1NOS3NOS2DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL919003 | 0.98 | NOS1 (0.51) | NOS1NOS3NOS2DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL919002 | 0.98 | NOS1 (0.51) | NOS1NOS3NOS2DPP4DPP8 | |
| Acetic Acid SCHEMBL9342261 | 0.94 | NOS1 (0.49) | NOS1NOS3NOS2DPP4DPP8 | |
| Leucine SCHEMBL29264283 | 0.86 | SLC7A5 (0.53) | NOS1NOS3NOS2CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163507-B | Recombinant antigen protein rP44-60 for detecting granulocytoplasmatic disease and kit containing antigen | 河套学院 | 2023-06-20 | — | — | CN | claimed |
| CN-114163507-A | Recombinant antigen protein rP44-60 for detecting granulocytic anaplasmosis and kit containing antigen | 河套学院 | 2022-03-11 | — | — | CN | claimed |
| CN-110269858-B | Twin medicine for treating ischemic stroke and preparation method thereof | 贵州医科大学 | 2021-07-09 | — | — | CN | claimed |
| EP-4733307-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND USING MIXED ANHYDRIDE PROCEDURE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-29 | — | — | EP | disclosed |
| CN-119841841-A | Cycloicaritin carbamate prodrug and salt thereof | 沈阳药科大学 | 2025-04-18 | — | — | CN | disclosed |
| EP-4538279-A2 | REACTION AGENT FOR AMIDE REACTIONS AND AMIDE COMPOUND PRODUCTION METHOD USING SAME | Chubu University Educational Foundation (JP) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025070753-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND USING MIXED ANHYDRIDE PROCEDURE | 中外製薬株式会社 | 2025-04-03 | — | — | WO | disclosed |
| US-20240425512-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | 280 BIO, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024254404-A2 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | 280 BIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-119101070-A | Nitrogen-containing heterocyclic compound, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-22 | — | — | US | disclosed |
| WO-1998006386-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
| WO-1998005625-A1 | DIAGNOSTIC IMAGING CONTRAST AGENT WITH IMPROVED IN-SERUM-RELAXIVITY | BRACCO S.P.A. (IT) | 1998-02-12 | — | — | WO | disclosed |
| US-5668291-A | THIOSUBSTITUTED PYRIDINES, TREATMENT OF AIDS AND HIV | WARNER-LAMBERT COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5668162-A | Isothiazolones lower plasma levels of lipoprotein(a) | WARNER-LAMBERT COMPANY | 1997-09-16 | — | — | US | disclosed |
| EP-0775110-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5620997-A | VIRICIDES, ANTIINFLAMMATORY AGENTS, ANTIATHEROSCLEROTIC AGENT | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996038144-A1 | ISOTHIAZOLONES | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996004242-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
| US-4766110-A | INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS | RYAN JAMES W (US) | 1988-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425512-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | KRAS, NRAS, HRAS | NOS1 407/4885NOS3 465/4885NOS2 704/4885 |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | NOS1 261/4885NOS3 397/4885NOS2 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.